80-OR: 670G Clinical Experience
| Autor: | Kristine Peterson, Barry P. Conrad, Marina Basina, Bruce A. Buckingham, David M. Maahs, Rayhan A. Lal, Korey K. Hood, Darrell M. Wilson, Annette Chmielewski, Jeannine Leverenz |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Type 1 diabetes medicine.medical_specialty Adult patients business.industry Endocrinology Diabetes and Metabolism Basal insulin 030209 endocrinology & metabolism medicine.disease 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Diabetes mellitus Family medicine Internal Medicine medicine Observational study business Carbohydrate intake Glycemic |
| Zdroj: | Diabetes. 68 |
| ISSN: | 1939-327X 0012-1797 |
| DOI: | 10.2337/db19-80-or |
| Popis: | Objective: In September 2016, the FDA approved the Medtronic 670G “hybrid” closed-loop system. In “Auto Mode,” this system automatically controls basal insulin delivery based on CGM data, but requires users to enter carbohydrate intake and blood sugar for boluses. Studies show improved time in range associated with the use of Auto Mode. In an effort to track our real-world experience with this first commercial closed-loop device, we followed pediatric and adult patients placed on the 670G. Methods: This was a 1-year prospective observational study, recruiting 5/2017-9/2018, of patients with type 1 diabetes, ≥7 years, starting the 670G system. Results: 84 patients started on the 670G (range 9-61 years), 26 (31%) were Conclusions: While use of closed-loop technology correlates with improved glycemic control, a focus on usability and human factors is necessary to ensure patients stay on treatment. Alarms and sensor calibration are a major patient concern, which next generation technology should alleviate. Disclosure R. Lal: Consultant; Self; Abbott. M. Basina: None. D.M. Maahs: Advisory Panel; Self; Novo Nordisk Inc. Consultant; Self; Abbott, Sanofi. Research Support; Self; Dexcom, Inc., Tandem Diabetes Care. B.A. Buckingham: Advisory Panel; Self; ConvaTec Inc., Novo Nordisk Inc., Profusa, Inc. Consultant; Self; Medtronic MiniMed, Inc. Research Support; Self; Beta Bionics, ConvaTec Inc., Dexcom, Inc., Insulet Corporation, Medtronic MiniMed, Inc., Tandem Diabetes Care. Other Relationship; Self; Insulet Corporation, Tandem Diabetes Care. K.K. Hood: Consultant; Self; Lilly Diabetes. Research Support; Self; Dexcom, Inc. Speaker's Bureau; Self; Johnson & Johnson Diabetes Institute. B.P. Conrad: None. J. Leverenz: None. A. Chmielewski: None. K. Peterson: None. D. Wilson: Advisory Panel; Self; Tolerion, Inc. Research Support; Self; Beta Bionics, Dexcom, Inc., Medtronic. Funding National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007217); Seiler Fund |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|